Berry Oncology HiFi Pan-cancer Screening

Chinese oncology company Berry Oncology has launched HiFi Pan-cancer Screening test, a multiple-cancer early screening product using whole-genome sequencing (WGS) of cell-free DNA (cfDNA). Built on the company's proprietary HiFi technology platform, the test can detect six high-risk and high-incident cancers in China, including lung, esophageal, gastric, liver, pancreatic, and colorectal cancers, with 87.6 percent sensitivity, 99.1 percent specificity, and 82 percent traceability accuracy, the company said.